Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Voices From mHealth 2015: Qualcomm Exec Urges Device Firms To Focus On Usability

This article was originally published in The Gray Sheet

Executive Summary

As Qualcomm Life continues to build partnerships that allow medical devices to connect through their 2net platform and share patient information, James Mault, the company's chief medical officer, emphasizes that companies should redesign products so they are more user-friendly for patients as devices move to the home setting in this "Gray Sheet" podcast.

You may also be interested in...



Qualcomm, Novartis Team Up For Remotely Monitored COPD Inhaler

In its continued bid to expand the reach of its 2net connected health system, Qualcomm is working with Novartis to develop a new inhaler for patients with chronic obstructive pulmonary disease that can be used to remotely monitor treatment effectiveness.

Growing Concerns With Cybersecurity Hacks of Devices

While the agency released its first guidance on cybersecurity requirements a decade ago, a top FDA official says the agency has seen a spike in potential vulnerabilities over the past year and a half, and has been working with manufacturers and other stakeholders to fix them before someone gets hurt.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Topics

UsernamePublicRestriction

Register

MT034389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel